Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female, 18 to 65 years of age, inclusive~* Current diagnosis of Irritable Bowel Syndrome (IBS)~* Subjects 50 years of age or older must have had a barium enema and flexible sigmoidoscopy or a colonoscopy and provide a record of this test~* Willing to participate in this study as evidenced by a signed, written informed consent form (ICF)~* If female and of child-bearing potential, willing to avoid pregnancy and practice adequate birth control from the time of study enrollment through at least 30 days after the final dose of study medication~* If female, negative pregnancy test results~* Right handed~* Ambulatory outpatient~* Agrees to refrain from blood donation during the course of the study~* Written and oral fluency in the English language~Exclusion Criteria:~* Evidence of structural abnormality of the gastrointestinal tract or GI diseases/conditions~* Current evidence or diagnosis of peptic ulcer~* Endoscopic bowel evaluation with evidence of cancer, inflammatory bowel disease, or other structural disease~* History of abdominal surgery such as adhesion lysis or any gastrointestinal surgery~* History of gastroesophageal reflux disease not controlled by a stable dose of medication~* Any evidence of or treatment of malignancy within the previous 5 years~* Clinical evidence of any disease that may interfere with participation in the study~* Existence of surgical or medical conditions which interfere with the absorption, distribution, metabolism and excretion of the study drug~* Symptoms of a significant clinical illness within the 2 weeks prior to Screening~* Type 1 diabetes mellitus, insulin-dependent Type 2 diabetes mellitus, and thyroid disorders or other endocrine disorders that are not well controlled by appropriate therapy~* A QTc interval of greater than or equal to 450 msec at Screening~* Presence of a psychotic disorder, bipolar disorder, alcohol or substance dependence (other than nicotine dependence) or eating disorder within the previous year according to DSM-IV-TR criteria~* Seizure disorder~* Subjects who have previously participated in a clinical trial for AV608 (previously known as NKP608 and CGP608)~* Positive drug test result at Screening~* Use of investigational drugs, products or devices within 30 days prior to Screening~* Planned use of certain drugs during the study that affect the central nervous system, gastrointestinal motility, autonomic activity or pain sensation~* Use of pimozide, terfenadine, astemizole, or cisapride during the study~* Presence of moderate or severe allergy~* Regular intake of more than 2 units of alcohol per day~* Pregnant or breast feeding~* Subjects with morbid obesity~* Subjects with metal implants or large tattoo~* Any clinically significant abnormalities on the Screening physical examination, ECG or laboratory tests~* Members of the investigative staff or their immediate family members~* Any other condition that the investigator believes would jeopardize the safety or rights of the subject or would render the subject unable to comply with the study protocol~* Regular use of more than 10 cigarettes per day

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues